H.R. 242House115th Congress (2017-2019)In Committee

Medicare Prescription Drug Price Negotiation Act of 2017

Introduced January 4, 2017

AI-Generated Summary

Updated April 15, 2026 at 11:18 AM UTC

The Medicare Prescription Drug Price Negotiation Act of 2017 would change the Social Security Act so that the Secretary of Health and Human Services must negotiate the prices of covered Part D drugs for Medicare beneficiaries. The goal is to lower the cost of prescription drugs that Medicare beneficiaries pay, without altering how drug plans choose which medicines to cover. The rule would apply to all Medicare Part D and Medicare Advantage prescription drug plans starting with the 2018 plan year.

Key Provisions

  • The Secretary of HHS is required to negotiate with drug manufacturers for lower prices, including discounts, rebates, and other concessions, for covered Part D drugs.
  • The negotiation authority does not let the Secretary set or require a specific drug formulary; plan sponsors can still choose their own formularies.
  • Plan sponsors (PDPs or MA‑PDs) may still obtain discounts that are better than the negotiated price.
  • The Secretary must submit semi‑annual reports to Congress detailing the negotiations, the prices achieved, and the discounts obtained.
  • The new negotiation requirement takes effect immediately upon enactment and applies to plan years beginning January 1, 2018.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

3 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

January 25, 2017

View full timeline
HouseIntro Referral

Introduced in House

January 4, 2017

HouseIntro Referral

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

January 4, 2017

HouseCommittee

Referred to the Subcommittee on Health.

January 13, 2017

HouseCommittee

Referred to the Subcommittee on Health.

January 25, 2017

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued January 4, 2017

I

115th CONGRESS

1st Session

H. R. 242

IN THE HOUSE OF REPRESENTATIVES

January 4, 2017

Mr. Welch (for himself, Ms. Schakowsky, Ms. DeLauro, Mr. Cummings, Mr. Ellison, Mr. Pocan, Mr. Cicilline, Ms. Kaptur, Mr. Lipinski, Ms. McCollum, Ms. Castor of Florida, Mr. Grijalva, Mr. Lynch, Mr. Cohen, Ms. Michelle Lujan Grisham of New Mexico, and Mr. Cartwright) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries.

1.

Short title

This Act may be cited as the Medicare Prescription Drug Price Negotiation Act of 2017.

2.

Negotiation of lower covered part D drug prices on behalf of medicare beneficiaries

(a)

Negotiation by secretary

Section 1860D–11 of the Social Security Act (42 U.S.C. 1395w–111) is amended by striking subsection (i) (relating to noninterference) and inserting the following:

(i)

Negotiation of Lower Drug Prices

(1)

In general

Notwithstanding any other provision of law, the Secretary shall negotiate with pharmaceutical manufacturers the prices (including discounts, rebates, and other price concessions) that may be charged to PDP sponsors and MA organizations for covered part D drugs for part D eligible individuals who are enrolled under a prescription drug plan or under an MA–PD plan.

(2)

No change in rules for formularies

(A)

In general

Nothing in paragraph (1) shall be construed to authorize the Secretary to establish or require a particular formulary.

(B)

Construction

Subparagraph (A) shall not be construed as affecting the Secretary's authority to ensure appropriate and adequate access to covered part D drugs under prescription drug plans and under MA–PD plans, including compliance of such plans with formulary requirements under section 1860D–4(b)(3).

(3)

Construction

Nothing in this subsection shall be construed as preventing the sponsor of a prescription drug plan, or an organization offering an MA–PD plan, from obtaining a discount or reduction of the price for a covered part D drug below the price negotiated under paragraph (1).

(4)

Semi-annual reports to Congress

Not later than June 1, 2018, and every 6 months thereafter, the Secretary shall submit to the Committees on Ways and Means, Energy and Commerce, and Oversight and Government Reform of the House of Representatives and the Committee on Finance of the Senate a report on negotiations conducted by the Secretary to achieve lower prices for Medicare beneficiaries, and the prices and price discounts achieved by the Secretary as a result of such negotiations.

.

(b)

Effective date

The amendment made by subsection (a) shall take effect on the date of the enactment of this Act and shall first apply to negotiations and prices for plan years beginning on January 1, 2018.